Medical Cannabis - United States

United States

The Medical Cannabis market in the United States is expected to see substantial growth in the coming years.
By 2024, the projected revenue for this market is estimated to be US$14.53bn.
This growth is anticipated to continue with an annual growth rate of 1.63% from 2024 to 2029.
As a result, the market volume is projected to reach US$15.75bn by 2029.
When compared globally, in the United States is expected to generate the highest revenue in the Medical Cannabis market, with US$14.53bn in 2024.
This indicates the significant market potential and demand for Medical Cannabis market products and services in the country.
In terms of per person revenues, in the United States is estimated to generate US$3.19k per person in 2024.
This figure highlights the economic impact and individual spending on Medical Cannabis market within the country.
The United States is experiencing a rapid growth in the medical cannabis market as more states legalize its use for therapeutic purposes.

Key regions: Spain, Europe, Australia, Germany, United States

Market

Region

Region comparison

Currency

Analyst Opinion

The Medical Cannabis market in United States has been experiencing significant growth and development in recent years.

Customer preferences: Customers in the United States are increasingly turning to medical cannabis as an alternative form of treatment for various health conditions. The shift towards natural and holistic remedies, coupled with growing awareness about the potential benefits of medical cannabis, has driven consumer preferences in this market.

Trends in the market: One prominent trend in the United States' Medical Cannabis market is the legalization of cannabis for medical purposes in an increasing number of states. This has led to a surge in demand for medical cannabis products and services, creating lucrative opportunities for businesses operating in this sector. Additionally, there is a growing trend towards research and development in medical cannabis, leading to the introduction of innovative products catering to specific medical needs.

Local special circumstances: The United States has a complex regulatory environment surrounding medical cannabis, with each state having its own set of laws and regulations governing its use. This patchwork of regulations has created challenges for businesses looking to operate across state lines, but it has also fostered a competitive market where companies must navigate varying legal frameworks to succeed.

Underlying macroeconomic factors: The growing acceptance of medical cannabis in the United States is also influenced by broader macroeconomic factors such as changing societal attitudes towards cannabis, increasing healthcare costs, and the need for alternative treatment options. As the market continues to evolve, economic factors play a crucial role in shaping the landscape for medical cannabis businesses in the United States.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.